FORTRESS BIOTECH INC (FBIO) Forecast, Price Target & Analyst Ratings
NASDAQ:FBIO • US34960Q3074
3.1061 USD
-0.17 (-5.3%)
Last: Mar 13, 2026, 12:59 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for FORTRESS BIOTECH INC (FBIO).
Forecast Snapshot
Consensus Price Target
$10.97
+ 253.02% Upside
Next Earnings Forecast
Release DateMar 24, 2026
PeriodQ4 / 2025
EPS Estimate$0.11
Revenue Estimate26.693M
ChartMill Buy Consensus
82.50%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$10.97
Upside
+ 253.02%
From current price of $3.11 to mean target of $10.97, Based on 8 analyst forecasts
Low
$4.55
Median
$10.97
High
$17.85
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
8 Wall Street analysts provided a forecast for the next 12 months for FBIO. The average price target is 10.97 USD. This implies a price increase of 253.02% is expected in the next year compared to the current price of 3.1061.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.50%
FBIO was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about FBIO.
In the previous month the buy percentage consensus was at a similar level.
FBIO was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-11 | Roth MKM | Reiterate | Buy -> Buy |
| 2024-11-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-07-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-20 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-05-16 | Roth MKM | Reiterate | Buy -> Buy |
| 2024-03-19 | Alliance Global Partners | Initiate | Buy |
| 2024-03-15 | Roth MKM | Reiterate | Buy |
| 2023-11-29 | Roth MKM | Maintains | Buy -> Buy |
| 2023-08-15 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-05-16 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2023-04-06 | Benchmark | Reiterate | Speculative Buy |
| 2022-08-04 | Ladenburg Thalmann | Initiate | Buy |
| 2022-07-14 | B. Riley Securities | Maintains | Buy |
| 2021-04-20 | Roth Capital | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 24, 2026
PeriodQ4 / 2025
EPS Estimate$0.11
Revenue Estimate26.693M
Revenue Q2Q76.54%
EPS Q2Q114.96%
Number of Analysts4
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
13.07%
EPS (1 Month)
0.00%
EPS (3 Months)
131.88%
Next Earnings Summary
FBIO is expected to report earnings on 3/24/2026. The consensus EPS estimate for the next earnings is 0.11 USD and the consensus revenue estimate is 26.69M USD.
The next earnings revenue estimate has been revised upward by 13.07% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 75.74M 10.10% | 84.513M 11.58% | 57.675M -31.76% | 74.808M 29.71% | 111.72M 49.34% | 148.21M 32.66% | 680.14M 358.90% | 721.75M 6.12% | 736.44M 2.04% | |
| EBITDA YoY % growth | -196.17M -12.81% | -133.245M 32.08% | -106.776M 19.86% | -54.774M 48.70% | -34.17M 37.62% | -12.342M 63.88% | N/A | N/A | N/A | |
| EBIT YoY % growth | -203.56M -13.72% | -139.242M 31.60% | -111.24M 20.11% | -65.051M 41.52% | -28.18M 56.68% | -12.342M 56.20% | 180.74M 1,564.43% | 195.84M 8.35% | 188.5M -3.75% | |
| Operating Margin | -268.76% | -164.76% | -192.87% | -86.96% | -25.22% | -8.33% | 26.57% | 27.13% | 25.60% | |
| EPS YoY % growth | -14.51 -5.15% | -8.97 38.18% | -3.27 63.55% | 0.32 109.83% | 0.01 -96.83% | 1.54 15,000.00% | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | |
|---|---|
| EPS Q2Q % growth | 0.11 114.96% |
| Revenue Q2Q % growth | 26.693M 76.54% |
| EBITDA Q2Q % growth | 8.874M 138.78% |
| EBIT Q2Q % growth | -8.415M 69.23% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
35.19%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
35.16%
Revenue Next 5 Year
64.44%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
23.67%
EBIT Next 5 Year
N/A
FORTRESS BIOTECH INC / FBIO Forecast FAQ
Can you provide the average price target for FORTRESS BIOTECH INC stock?
8 analysts have analysed FBIO and the average price target is 10.97 USD. This implies a price increase of 253.02% is expected in the next year compared to the current price of 3.1061.
Can you provide the upcoming earnings date for FORTRESS BIOTECH INC?
FORTRESS BIOTECH INC (FBIO) will report earnings on 2026-03-24, after the market close.
Can you provide the consensus estimates for FORTRESS BIOTECH INC next earnings?
The consensus EPS estimate for the next earnings of FORTRESS BIOTECH INC (FBIO) is 0.11 USD and the consensus revenue estimate is 26.69M USD.
Can you provide the expected long term growth rate for FORTRESS BIOTECH INC stock?
The expected long term growth rate for FORTRESS BIOTECH INC (FBIO) is 35.16%.